Summary: Results of a clinical trial of Axona show the medical food may be an effective treatment for people with mild to moderate Alzheimer’s, at least for those who don’t have the APOE4 genetic variation. Accera is planning a larger trial to confirm these results.
The company is also planning an imaging study to try to prove that treatment with Axona changes the metabolism of certain areas of the brain, and that those changes are linked with improvements in cognition. If successful, Accera could be among the first to show that changes to a “biomarker” reflect real changes in memory and thinking.
I’ve written before about Accera’s Axona, a medical food available by prescription for people diagnosed with mild to moderate Alzheimer’s. The theory behind Axona is that if brain cells aren’t getting or using enough glucose, you can substitute ketone bodies for glucose. A ketone body is a substance created when fats are broken down in the body. Axona increases the level of ketone bodies in the blood, and in theory, provides an alternate fuel for brain cells.
Last week, I talked with Steve Orndorff, President and CEO of Accera, to get an update on his company’s product. Data from an initial trial of Axona have now been published, and the results are encouraging enough for Accera to plan a larger clinical trial, he says.